Stocktoria
Entrada Therapeutics, Inc. TRDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-29
Chart by TradingView
2/9
Piotroski F — financial health
4.24
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
| Ratios | |||||
| Operating margin | -621.1% | 22.3% | -2.5% | — | — |
| Net margin | -565.5% | 31.1% | -5.2% | — | — |
| FCF margin | -509.6% | -21.2% | 104.0% | — | — |
| Return on assets | -38.1% | 12.5% | -1.4% | -37.5% | -16.7% |
| Return on equity | -47.0% | 15.3% | -2.8% | -44.5% | -17.1% |
| Current ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 |
| Revenue growth | -87.9% | 63.4% | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 202,084 | $2.6M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.24 (safe)
- Working capital / assets 0.747
- Retained earnings / assets -0.724
- EBIT / assets -0.418
- Equity / liabilities 4.297
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001689375 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.